BCMA-GPRC5D CAR-T cells

Phase 2Cell therapy

SShenzhen University General Hospital

BCMA-GPRC5D CAR-T cells is one of 39 biologic programs targeting Multiple Myeloma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Multiple MyelomaRecruiting

Multiple MyelomaPhase 2

Recruiting

Competition

Competitive Landscape

258 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Belamaf

GSK

Phase 3

39 2

Empliciti

Bristol-Myers Squibb

Phase 3

43 3

Venclexta

AbbVie

Phase 3

17 4

Keytruda

Merck & Co.

Phase 3

17 5

Opdivo

Bristol-Myers Squibb

Phase 3

11 6

Xpovio

KKaryopharm Therapeutics Inc

Phase 3

28 7

Treanda

AAzurity Pharmaceuticals

Phase 3

19 8

Neulasta

Amgen

Phase 3

5 9

Cytosar

Teva

Phase 3

4 10

Busulfex

Akero Therapeutics

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Multiple Myeloma1 trial

BCMA-GPRC5D CAR-T Therapy in Relapsed or Refractory Multiple Myeloma

Recruiting·SShenzhen University General Hospital·Phase 1/2·NCT06644443·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for BCMA-GPRC5D CAR-T cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BCMA-GPRC5D CAR-T cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BCMA-GPRC5D CAR-T cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen University General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: SShenzhen University General Hospital

BCMA-GPRC5D CAR-T cells

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News